Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1017/S0012162205001325 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Endovascular Treatment of Malfunctioning Dialysis Fistulas: A Multicenter Retrospective Analysis Comparing Transradial and Conventional Transvenous Access.
Catheter Cardiovasc Interv
December 2024
Radiology Unit, University Hospital Dulbecco, Catanzaro, Italy.
Background: Venous outflow is the favored access for endovascular management of dialysis fistulas. However, transradial access (TRA) offers advantages in specific clinical scenarios. The study aims to compare the efficacy, feasibility, and safety of TRA and transvenous access (TVA) in the endovascular management of malfunctioning dialysis fistulas, addressing the existing gap in comprehensive literature.
View Article and Find Full Text PDFThe evaluation of the two-dimensional gamma passing rate efficiency for the unilateral breast cancer dosimetry using the Intensity-Modulated Radiation Therapy.
J Pak Med Assoc
October 2024
Department of Surgery, Baghdad University, Baghdad, Iraq.
Article Synopsis
- - The study aimed to assess the effectiveness of the two-dimensional gamma passing rate of 3%/3mm for women with unilateral breast cancer, conducted in Baghdad from November 2021 to April 2022.
- - Female patients underwent CT simulations and were treated using an intensity-modulated radiation therapy approach, with evaluations based on two dosimetry methods: 3%/3mm and 3%/2mm at different thresholds.
- - Results showed that the 3%/3mm criterion performed better than the 3%/2mm for assessing doses, suggesting 3%/2mm should be reserved for cases with higher risks to organs while 3%/3mm is appropriate for simpler scenarios.
Intensity-modulated radiotherapy (IMRT) versus three-dimensional conformal radiotherapy (3DCRT) as treatment plans for head and neck tumours.
J Pak Med Assoc
October 2024
Department of Radiotherapy, Al-Amal National Hospital for Cancer Treatment, Baghdad Medical City, Iraqi Ministry of Health, Baghdad, Iraq.
Objective: To compare intensity-modulated radiation therapy with three-dimensional conformal radiation therapy 3DCRTwith respect to dose coverage for target volume.
Methods: The cross-sectional study was conducted at Al-Amal National Hospital, Baghdad, Iraq, from November 2020 to March 2021 and comprised patients with head and neck cancerous tumours. The patients underwent computed tomography scans, and were subsequently subjected to three-dimensional conformal radiotherapy and intensity-modulated radiotherapy treatment planning techniques on the basis of Monaco 5.
IBD Patients with Primary or Secondary Nonresponse to Ustekinumab Benefit from Dose Escalation or Reinduction.
J Clin Med
July 2024
Division of Gastroenterology, Hepatology, and Nutrition, Department of Life, Health and Environmental Sciences, University of L'Aquila, 67100 L'Aquila, Italy.
Ustekinumab is a monoclonal antibody approved for the treatment of IBD. This drug has a well-established efficacy; however, patients may not respond or lose response. The availability of other biological therapies prompts the need for comparative data between different agents to suggest first- or second-line strategies.
View Article and Find Full Text PDFSARS-CoV-2 Viral Load in the Nasopharynx at Time of First Infection Among Unvaccinated Individuals: A Secondary Cross-Protocol Analysis of 4 Randomized Trials.
JAMA Netw Open
May 2024
Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington.
Importance: SARS-CoV-2 viral load (VL) in the nasopharynx is difficult to quantify and standardize across settings, but it may inform transmission potential and disease severity.
Objective: To characterize VL at COVID-19 diagnosis among previously uninfected and unvaccinated individuals by evaluating the association of demographic and clinical characteristics, viral variant, and trial with VL, as well as the ability of VL to predict severe disease.
Design, Setting, And Participants: This secondary cross-protocol analysis used individual-level data from placebo recipients from 4 harmonized, phase 3 COVID-19 vaccine efficacy trials sponsored by Moderna, AstraZeneca, Janssen, and Novavax.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!